|
1) Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005; 5: 311-21
|
|
|
|
2) Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3: 730-7
|
|
|
|
|
3) Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004; 5: 738-43
|
|
|
|
|
|
4) Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425: 841-6
|
|
|
|
|
|
5) Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005; 121: 1109-21
|
|
|
|
|
|
6) Ninomiya M, Abe A, Katsumi A, et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia. 2007; 21: 136-42
|
|
|
|
|
|
7) Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003; 423: 255-60
|
|
|
|
|
|
8) Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003; 423: 302-5
|
|
|
|
|
|
9) Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004; 21: 843-51
|
|
|
|
|
|
10) Kato Y, Iwama A, Tadokoro Y, et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med. 2005; 202: 169-79
|
|
|
|
|
|
11) Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434: 843-50
|
|
|
|
|
|
12) Suzuki T, Chiba S. Notch signaling in hematopoietic stem cells. Int J Hematol. 2005; 82: 285-94
|
|
|
|
|
13) Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351: 657-67
|
|
|
|
|
|
14) Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8; 21 chromosomal translocation. Proc Natl Acad Sci U S A. 2000; 97: 7521-6
|
|
|
|
|
|
15) Jamieson CH, Weissman IL, Passegue E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell. 2004; 6: 531-3
|
|
|
|
|
|
16) Cozzio A, Passegue E, Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003; 17: 3029-35
|
|
|
|
|
|
17) Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006; 442: 818-22
|
|
|
|
|
|
18) Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006; 441: 475-82
|
|
|
|
|
|
19) Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 2006; 441: 518-22
|
|
|
|
|
|
20) Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005; 105: 2527-34
|
|
|
|
|
|
21) Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2006; 107: 1149-55
|
|
|
|
|
|
22) Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14: 1777-84
|
|
|
|
|
|
23) Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997; 89: 3104-12
|
|
|
|
|
|
24) Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(＋)/CD71(-)/HLA-DR. Blood. 1998; 92: 4325-35
|
|
|
|
|
|
25) Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol. 2000; 28: 660-71
|
|
|
|
|
|
26) van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007; 110: 2659-66
|
|
|
|
|
|
27) Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007; 104: 11008-13
|
|
|
|
|
|
28) Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood. 2000; 95: 1007-13
|
|
|
|
|
|
29) Liu J, Jiang G. CD44 and hematologic malignancies. Cell Mol Immunol. 2006; 3: 359-65
|
|
|
|
|
|
30) Bendall LJ, Bradstock KF, Gottlieb DJ. Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34＋ cells. Leukemia. 2000; 14: 1239-46
|
|
|
|
|
|
31) Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12: 1167-74
|
|
|
|
|
|
32) Krause DS, Lazarides K, von Andrian UH, et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006; 12: 1175-80
|
|
|
|
|
|
33) Williams DA, Cancelas JA. Leukaemia: niche retreats for stem cells. Nature. 2006; 444: 827-8
|
|
|
|
|
|
34) Peterson LF, Wang Y, Lo MC, et al. The multi-functional cellular adhesion molecule CD44 is regulated by the 8; 21 chromosomal translocation. Leukemia. 2007; 21: 2010-9
|
|
|
|
|
|
35) Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007; 109: 58-60
|
|
|
|
|
|
36) Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006; 66: 7445-52
|
|
|
|
|